Firefly and NeuroSigma Partnered for ADHD Therapy Access
The collaboration aims to connect clinicians with non-drug treatment options for pediatric ADHD patients.
Updated on Sept. 25, 2026 in Alzheimer’s

Live Poll
Do you support prioritizing non-drug therapies for children diagnosed with ADHD?
Firefly Neuroscience has partnered with NeuroSigma to expand access to the Monarch eTNS System, a non-drug therapy for children with ADHD. This collaboration leverages Firefly's data platform to introduce the treatment to clinical practices across the U.S.
Why it matters
The partnership targets a significant treatment gap for the millions of children currently diagnosed with ADHD who receive no therapy. By combining brain function data with non-medication alternatives, the initiative seeks to provide more objective insights and clinical options.
The FDA cleared the Monarch eTNS System for children ages 7 through 12. Firefly Neuroscience maintains an Evoke database containing over 200,000 brain scans.
The players
Firefly Neuroscience
This company specializes in using AI and neuro-data to provide objective insights into brain health and neurological conditions.
NeuroSigma
This bioelectronic medical device company develops technology for the treatment of neurological and neuropsychiatric disorders.
The details
Firefly will utilize its proprietary Evoke platform to introduce the Monarch device, which delivers external trigeminal nerve stimulation via a forehead patch while the child sleeps. The move follows a surge in interest for the device, which currently holds a waitlist of over 1,500 patients, caregivers, and providers.
Timeline
March 2026: Firefly identified EEG/ERP biomarkers for ADHD presentations.
July 2026: NeuroSigma launched U.S. sales for the Monarch device.
September 2026: NeuroSigma expanded third-party installment payment options.
September 25, 2026: Firefly shares increased 42.01 percent.
Health Landscape
The partnership follows the regulatory standards established by the FDA pediatric ADHD device clearance protocols for non-pharmacological interventions. This marks a shift toward integrating digital brain data with medical hardware to fill the void for children who remain untreated by traditional medication.
Families may gain improved access to non-drug treatment alternatives that utilize sleep-based stimulation technology. Patients and caregivers currently on the waitlist should consult their providers regarding how this partnership may expedite their access to the Monarch system.
The takeaway
This collaboration highlights the growing role of data-driven diagnostics in supporting non-pharmacological pediatric treatments. Interested families should track updates from their pediatricians as the companies integrate these technologies into routine clinical care.
Further reading
Learn more about the latest innovations in neuro-health at the Alzheimer’s section.
Live Poll
Do you support prioritizing non-drug therapies for children diagnosed with ADHD?






